At 26, Neena Bitritto-Garg sent a pivotal email to her CEO at Eisai, expressing concerns about a study on Alzheimer’s that highlighted a potential imbalance of APOE gene carriers. Her warnings went unheeded, and when the presentation proceeded without her subgroup suggestions, Biogen’s stock fell as she predicted. This experience later positioned her to negotiate a licensing deal for her new company, Ensho Therapeutics, which focused on inflammatory bowel disease, capitalizing on industry interest after a competing biotech’s acquisition. Despite facing challenges in fundraising and formulation, Bitritto-Garg is now poised to advance her lead asset, NSHO-101, into clinical studies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/business/an-early-career-stand-proved-this-young-biotech-exec-had-what-it-takes
